Form 8-K - Current report:
SEC Accession No. 0001437749-24-034011
Filing Date
2024-11-08
Accepted
2024-11-07 17:35:43
Documents
16
Period of Report
2024-11-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ctdh20241107_8k.htm   iXBRL 8-K 34592
2 EXHIBIT 10.1 ex_744461.htm EX-10.1 68850
3 EXHIBIT 10.2 ex_744462.htm EX-10.2 79350
  Complete submission text file 0001437749-24-034011.txt   371586

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ctdh-20241107.xsd EX-101.SCH 3891
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ctdh-20241107_def.xml EX-101.DEF 13443
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctdh-20241107_lab.xml EX-101.LAB 17670
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctdh-20241107_pre.xml EX-101.PRE 13420
18 EXTRACTED XBRL INSTANCE DOCUMENT ctdh20241107_8k_htm.xml XML 4792
Mailing Address PO BOX 1180 ALACHUA FL 32616-1180
Business Address 6714 NW 16TH STREET, SUITE B GAINESVILLE FL 32653 386-418-8060
Cyclo Therapeutics, Inc. (Filer) CIK: 0000922247 (see all company filings)

EIN.: 593029743 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39780 | Film No.: 241437290
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)